SCHEMBL19902592

SCHEMBL19902592

O=c1[nH]nc(C2CCC(O)CC2)c2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
LMNA P02545 1/20 0.42
PRMT5 O14744 1/20 0.41
PARP1 P09874 4/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
ROCK2 O75116 4/20 0.40
ROCK1 Q13464 3/20 0.40
POLB P06746 3/20 0.40
PARP2 Q9UGN5 1/20 0.40
PARP3 Q9Y6F1 1/20 0.40
AR P10275 1/20 0.40
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1789261 0.92 ATM (0.50) ATMNPSR1LMNAPRMT5PARP1
SCHEMBL1786994 0.85 PRMT5 (0.48) ATMNPSR1LMNAPRMT5PARP1
SCHEMBL1786583 0.85 ATM (0.47) ATMNPSR1LMNAPRMT5PARP1
SCHEMBL19902331 0.84 PRMT5 (0.45) ATMNPSR1LMNAPRMT5PARP1
SCHEMBL19902312 0.84 PRMT5 (0.45) ATMNPSR1LMNAPRMT5PARP1
SCHEMBL19902284 0.84 PRMT5 (0.45) ATMNPSR1LMNAPRMT5PARP1
SCHEMBL1790181 0.84 PRMT5 (0.47) ATMNPSR1LMNAPRMT5PARP1
SCHEMBL19902523 0.84 ROCK1 (0.44) ATMNPSR1LMNAPRMT5PARP1
SCHEMBL19902529 0.84 LMNA (0.46) ATMNPSR1LMNAPARP1KDM4E
SCHEMBL12845934 0.83 ATM (0.45) ATMNPSR1LMNAPRMT5PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 ATM 1521/4885NPSR1 2874/4885LMNA 1620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.